Related Experiment Videos
Trisomy 20 in acute myelogenous leukemia
L Attas1, S M Lichtman, D R Budman
1Don Monti Division of Oncology, Department of Medicine, North Shore University Hospital, Manhasset, New York.
Cancer Genetics and Cytogenetics
|May 1, 1989
Summary
A patient with acute myelomonocytic leukemia and trisomy 20 achieved a complete response to standard therapy. This case highlights the importance of understanding chromosomal abnormalities in leukemia treatment.
Area of Science:
- Hematology
- Cytogenetics
- Oncology
Background:
- Acute myelomonocytic leukemia (AMML) is a subtype of leukemia.
- Chromosomal abnormalities play a crucial role in leukemia development and prognosis.
- Trisomy 20 is a rare chromosomal abnormality observed in hematological malignancies.
Observation:
- A patient diagnosed with acute myelomonocytic leukemia presented with trisomy 20 in bone marrow cells.
- This specific chromosomal abnormality was identified through cytogenetic analysis.
Findings:
- The patient achieved a complete response following standard antileukemic therapy.
- The presence of trisomy 20 did not impede successful treatment outcomes with conventional chemotherapy.
Implications:
- This case suggests that trisomy 20 may not be a negative prognostic factor in all cases of AMML.
- Further research into the role of trisomy 20 in acute myeloid leukemia is warranted.
- Understanding the impact of specific chromosomal aberrations on treatment response is vital for personalized medicine in oncology.